Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients

Nagio Takigawa, Yoshihiko Segawa, Yoshinobu Maeda, Ichiro Takata, Nobukazu Fujimoto

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Serum hepatocyte growth factor/scatter factor (HGF/SF) levels were measured in 25 patients with small cell lung cancer (SCLC), 16 patients with benign lung diseases and 15 healthy subjects with an enzyme-linked immunosorbent assay. The patients with SCLC did not have bacterial or interstitial pneumonia. Patients with benign lung diseases included eight with bacterial pneumonia, three with interstitial pneumonia, and five with benign lung tumor. Serum HGF/SF levels were significantly higher in patients with SCLC (mean ± S.D.: 0.40±0.17 ng/ml) than in healthy subjects (0.26±0.093 ng/ml) (P=0.0083). Patients with bacterial pneumonia had significantly higher serum HGF/SF (0.52±0.19 ng/ml) than did those with benign lung tumors (0.27±0.058 ng/ml) and healthy subjects (P=0.013 and P=0.0019, respectively). By clinical stage of SCLC, HGF/SF levels were 0.34±0.12 and 0.47±0.20 ng/ml in patients with limited disease and extensive disease, respectively; this difference was not significant (P=0.080). Although serum HGF/SF levels were increased in patients with SCLC, this increase might not have been related to tumor burden.

Original languageEnglish
Pages (from-to)211-218
Number of pages8
JournalLung Cancer
Volume17
Issue number2-3
DOIs
Publication statusPublished - Jul 1997
Externally publishedYes

Fingerprint

Hepatocyte Growth Factor
Small Cell Lung Carcinoma
Serum
Bacterial Pneumonia
Healthy Volunteers
Interstitial Lung Diseases
Lung Diseases
Lung
Tumor Burden
Neoplasms
Enzyme-Linked Immunosorbent Assay

Keywords

  • Bacterial pneumonia
  • Carcinoembryonic antigen
  • Enzyme-linked immunosorbent assay
  • Hepatocyte growth factor/scatter factor
  • Small cell lung cancer
  • Tumor marker

ASJC Scopus subject areas

  • Oncology

Cite this

Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients. / Takigawa, Nagio; Segawa, Yoshihiko; Maeda, Yoshinobu; Takata, Ichiro; Fujimoto, Nobukazu.

In: Lung Cancer, Vol. 17, No. 2-3, 07.1997, p. 211-218.

Research output: Contribution to journalArticle

Takigawa, Nagio ; Segawa, Yoshihiko ; Maeda, Yoshinobu ; Takata, Ichiro ; Fujimoto, Nobukazu. / Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients. In: Lung Cancer. 1997 ; Vol. 17, No. 2-3. pp. 211-218.
@article{20161a459b3042f3b420627b6b1315d5,
title = "Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients",
abstract = "Serum hepatocyte growth factor/scatter factor (HGF/SF) levels were measured in 25 patients with small cell lung cancer (SCLC), 16 patients with benign lung diseases and 15 healthy subjects with an enzyme-linked immunosorbent assay. The patients with SCLC did not have bacterial or interstitial pneumonia. Patients with benign lung diseases included eight with bacterial pneumonia, three with interstitial pneumonia, and five with benign lung tumor. Serum HGF/SF levels were significantly higher in patients with SCLC (mean ± S.D.: 0.40±0.17 ng/ml) than in healthy subjects (0.26±0.093 ng/ml) (P=0.0083). Patients with bacterial pneumonia had significantly higher serum HGF/SF (0.52±0.19 ng/ml) than did those with benign lung tumors (0.27±0.058 ng/ml) and healthy subjects (P=0.013 and P=0.0019, respectively). By clinical stage of SCLC, HGF/SF levels were 0.34±0.12 and 0.47±0.20 ng/ml in patients with limited disease and extensive disease, respectively; this difference was not significant (P=0.080). Although serum HGF/SF levels were increased in patients with SCLC, this increase might not have been related to tumor burden.",
keywords = "Bacterial pneumonia, Carcinoembryonic antigen, Enzyme-linked immunosorbent assay, Hepatocyte growth factor/scatter factor, Small cell lung cancer, Tumor marker",
author = "Nagio Takigawa and Yoshihiko Segawa and Yoshinobu Maeda and Ichiro Takata and Nobukazu Fujimoto",
year = "1997",
month = "7",
doi = "10.1016/S0169-5002(97)00651-X",
language = "English",
volume = "17",
pages = "211--218",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients

AU - Takigawa, Nagio

AU - Segawa, Yoshihiko

AU - Maeda, Yoshinobu

AU - Takata, Ichiro

AU - Fujimoto, Nobukazu

PY - 1997/7

Y1 - 1997/7

N2 - Serum hepatocyte growth factor/scatter factor (HGF/SF) levels were measured in 25 patients with small cell lung cancer (SCLC), 16 patients with benign lung diseases and 15 healthy subjects with an enzyme-linked immunosorbent assay. The patients with SCLC did not have bacterial or interstitial pneumonia. Patients with benign lung diseases included eight with bacterial pneumonia, three with interstitial pneumonia, and five with benign lung tumor. Serum HGF/SF levels were significantly higher in patients with SCLC (mean ± S.D.: 0.40±0.17 ng/ml) than in healthy subjects (0.26±0.093 ng/ml) (P=0.0083). Patients with bacterial pneumonia had significantly higher serum HGF/SF (0.52±0.19 ng/ml) than did those with benign lung tumors (0.27±0.058 ng/ml) and healthy subjects (P=0.013 and P=0.0019, respectively). By clinical stage of SCLC, HGF/SF levels were 0.34±0.12 and 0.47±0.20 ng/ml in patients with limited disease and extensive disease, respectively; this difference was not significant (P=0.080). Although serum HGF/SF levels were increased in patients with SCLC, this increase might not have been related to tumor burden.

AB - Serum hepatocyte growth factor/scatter factor (HGF/SF) levels were measured in 25 patients with small cell lung cancer (SCLC), 16 patients with benign lung diseases and 15 healthy subjects with an enzyme-linked immunosorbent assay. The patients with SCLC did not have bacterial or interstitial pneumonia. Patients with benign lung diseases included eight with bacterial pneumonia, three with interstitial pneumonia, and five with benign lung tumor. Serum HGF/SF levels were significantly higher in patients with SCLC (mean ± S.D.: 0.40±0.17 ng/ml) than in healthy subjects (0.26±0.093 ng/ml) (P=0.0083). Patients with bacterial pneumonia had significantly higher serum HGF/SF (0.52±0.19 ng/ml) than did those with benign lung tumors (0.27±0.058 ng/ml) and healthy subjects (P=0.013 and P=0.0019, respectively). By clinical stage of SCLC, HGF/SF levels were 0.34±0.12 and 0.47±0.20 ng/ml in patients with limited disease and extensive disease, respectively; this difference was not significant (P=0.080). Although serum HGF/SF levels were increased in patients with SCLC, this increase might not have been related to tumor burden.

KW - Bacterial pneumonia

KW - Carcinoembryonic antigen

KW - Enzyme-linked immunosorbent assay

KW - Hepatocyte growth factor/scatter factor

KW - Small cell lung cancer

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0030844390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030844390&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(97)00651-X

DO - 10.1016/S0169-5002(97)00651-X

M3 - Article

C2 - 9237156

AN - SCOPUS:0030844390

VL - 17

SP - 211

EP - 218

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2-3

ER -